Nephrotoxicity pp 331-336 | Cite as

Distribution of Platinum Amongst the Subcellular Organelles of the Rat Kidney After Oral Administration of Cisplatin

  • S. P. Binks
  • M. Dobrota


Cisplatin is an effective anticancer agent when administered i. v. to experimental animals and man (1). Its use, however is limited by its toxicity to a number of organs including the kidney (2). These side effects can be modulated by the use of second generation analogues such as carboplatin (3) and alternative routes of administration. Recent studies have demonstrated that cisplatin is orally absorbed, that the nephrotoxicity associated with the compound could be significantly reduced using this route and that oral cisplatin is effective against several murine tumours (4). We have previously reported that oral cisplatin (in rats) could potentiate its hepatotoxicity, although the greatest proportion of the absorbed Pt is still associated with the kidney (5). In this study we have examined the uptake and subcellular localization of platinum in the rat kidney cortex following oral administration of cisplatin with the aim of identifying the sites of Pt accumulation and relating this to the nephrotoxicity.


Toxicity Phosphorus Platinum Sedimentation Chlorine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Prestayko, A., D’Aoust, J., Issell, B. and Crooke, S. (1979). Cisplatin (cis-diamino-dichloroplatinum II). Cancer Treat Rev 5: 17–39.CrossRefGoogle Scholar
  2. 2.
    Goldstein, R. and Mayor G. (1983). The nephrotoxicity of cisplatin Life Sciences 32: 685–690.PubMedCrossRefGoogle Scholar
  3. 3.
    Barnard, C., Cleare, M. and Hydes, P. (1986). Second generation anticancer platinum compounds. Chem. Brit. 22 : 1001–1004.Google Scholar
  4. 4.
    Siddik, Z., Boxall, F., Goddard, P., Barnard, C. and Harrap, K. (1984). Antitumour, Pharmacokinetic and toxicity studies with orally administered cisplatin, CBDC and CHIP. Proc Amer Assoc Cancer Res 25: 369.Google Scholar
  5. 5.
    Binks, S. and Dobrota, M. (1986). Comparative study of cisplatin toxicity and route of administration. Biochem. Soc. Trans, 14: 694–695.Google Scholar
  6. 6.
    Andersen, K.J., Haga, H.J. and Dobrota, M. (1987) . Lysosomes of the renal cortex: Heterogeneity and role in protein handling, Kidney Internat. 31: 886–897.CrossRefGoogle Scholar
  7. 7.
    Galle, P. (1983). The role of lysosomes in the renal concentration of mineral elements. In: “Advances in Nephrology”, Vol 12, eds. Hamburger, J., Crosnier, J., Grunfeld, J.P. and Maxwell, M.H. Year Book Medical Publishers, Chicago.Google Scholar
  8. 8.
    Ghadially, F.N., Lalonde, J.M.A. and Yang-Steppuhn, S. (1982). Uraniosomes produced in cultured rabbit kidney cells by uranyl acetate. Virchows Arch (Cell Pathol) 39: 21–30.CrossRefGoogle Scholar
  9. 9.
    Sharma, R.P. and Edwards, I.R. (1983). Cis-Platinum: Subcellular distribution and binding to cytosolic ligands. Biochem. Pharmacol 32: 2665–2669.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • S. P. Binks
    • 1
  • M. Dobrota
    • 1
  1. 1.Robens Institute of Industrial and Environmental Health and SafetyUniversity of SurreyGuildford, SurreyUK

Personalised recommendations